Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | TACR2 | P21452 | 3/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128283 | 0.96 | CNR1 (0.46) | CNR1CNR2CHRNA7TACR2TACR1 | |
| SCHEMBL1128277 | 0.95 | CNR1 (0.39) | CNR1CNR2CHRNA7TACR2TACR1 | |
| SCHEMBL1988809 | 0.94 | CNR1 (0.39) | CNR1CNR2CHRNA7TACR2TACR1 | |
| SCHEMBL1987975 | 0.93 | CNR1 (0.37) | CNR1CNR2CHRNA7TACR2TACR1 | |
| SCHEMBL1983850 | 0.91 | CNR1 (0.45) | CNR1CNR2CHRNA7TACR2TACR1 | |
| SCHEMBL1986474 | 0.90 | CNR1 (0.44) | CNR1CNR2CHRNA7TACR2TACR1 | |
| SCHEMBL1987792 | 0.89 | NPC1 (0.36) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL1991445 | 0.89 | CNR1 (0.37) | CNR1CNR2CHRNA7TACR2TACR1 | |
| SCHEMBL1987894 | 0.88 | CNR1 (0.45) | CNR1CNR2CHRNA7TACR2TACR1 | |
| SCHEMBL1984654 | 0.87 | CNR1 (0.44) | CNR1CNR2CHRNA7TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680102-B2 | Pyrrole derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2014-03-25 | — | — | US | disclosed |
| US-8680102-B2 | Pyrrole derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2014-03-25 | — | — | US | disclosed |
| US-20110152320-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
| US-20110152320-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
| US-20110152320-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152320-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885CHRNA7 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.